Aimmune
is a biopharmaceutical company that develops and commercializes novel therapeutics for the treatment of food allergies... Read moreAimmune
is a biopharmaceutical company that develops and commercializes novel therapeutics for the treatment of food allergies... Read more
News
Jul 21, 2025
Law 360
Aimmune: Aimmune Investors' $27.5M Deal In Nestle Suit Gets Final OK
Mar 21, 2025
PR Newswire
Press Release: Aimmune : Monteverde & Associates PC and Kahn Swick & Foti, LLC Announce Proposed Class Action Settlement on Behalf of All Former Holders of Aimmune Therapeutics, Inc. Common Stock
Feb 28, 2025
Law 360
Aimmune: Aimmune Shareholders' $27.5M Deal Over Sale To Nestle OK'd
Oct 13, 2022
Benzinga
Aimmune: Allergy Partners Announces Collaboration with Aimmune Therapeutics to Provide PALFORZIA [Peanut (Arachis hypogaea) Allergen Powder-dnfp] Directly to Patients
Jun 30, 2022
FinanzNachrichten
Aimmune: Aimmune Therapeutics, Inc.: Aimmune Therapeutics to Present New Data for PALFORZIA [Peanut (Arachis hypogaea) Allergen Powder-dnfp] at the EAACI Hybrid Congress 2022
Feb 15, 2022
Acrofan
Aimmune: Aimmune Therapeutics Announces Publication of Pooled Safety Analysis of PALFORZIA Treatment for up to 2 Years in the Journal of Allergy and Clinical
Dec 22, 2021
MarketScreener
Aimmune: Aimmune's PALFORZIA [defatted powder of Arachis hypogaea L., semen (peanuts)] Receives Final Appraisal Determination (FAD) as Positive Draft Guidance From NICE for the Treatment of Peanut Allergy in Patients Aged 4 to 17 Years
Nov 13, 2021
IndianWeb2
Aimmune: Aimmune Therapeutics Presents New PALFORZIA [Peanut (Arachis hypogaea) Allergen Powder-dnfp] Data on Immunological Outcomes of Long-Term Daily Oral Immunotherapy at the EAACI PAAM Digital Meeting
Nov 05, 2021
MarketScreener
Aimmune: Aimmune Therapeutics to Present New Data at ACAAI on the Real-World Burden of Peanut Allergy and Early Physician Experience with PALFORZIA in Clinical Practice in the U.S.
Aug 03, 2021
Acrofan
Aimmune: Aimmune's PALISADE-ARC004 Longitudinal Study Showed PALFORZIA Safety and Efficacy Increased Over Time in Patients with Peanut Allergy
Aimmune Competitors
1
2
3
4
5
6
7
8
9
10